Raajit Rampal is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 561 publications with 11,338 citations (h-index 59); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
Memorial Sloan-Kettering Cancer Center
New York, NY 100656007
Telephone
212-639-2194Registry record last updated 8 Jan 2013.
Clinical trials
- A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
23 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20257 payments$41,161openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202517 payments$22,691openpaymentsdata.cms.gov ↗
- Incyte CorporationProgram year202520 payments$21,348openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Core D: Biomarker and Bio-Informatics Core
Icahn School of Medicine at Mount Sinai
FY2026$624,089P01CA108671 - Evaluation of genetic and epigenetic determinants of response in patients with accelerated and blast phase Myeloproliferative Neoplasm (MPNs)
Sloan-Kettering Inst Can Research
FY2026$444,590R21CA313410 - Core D: Biomarker and Bio-Informatics Core
Icahn School of Medicine at Mount Sinai
FY2025$624,089P01CA108671
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
Journal of Clinical Oncology
2023 - NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Journal of the National Comprehensive Cancer Network
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”